Neuren Pharmaceuticals Limited (AU:NEU) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neuren Pharmaceuticals Limited (NEU) has requested an immediate trading halt of its securities on the ASX, pending the release of top line results from its Phase 2 clinical trial for NNZ-2591 in Angelman syndrome. The halt will remain until the market announcement is made or until normal trading resumes on Friday, 9 August 2024. This strategic pause anticipates significant company news that could impact stock performance.
For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.